Covance Recognized for Outstanding Performance by Merck & Co., Inc.

PRINCETON, N.J., July 31 /PRNewswire-FirstCall/ -- Covance Inc.
(NYSE: CVD), a leading provider of drug development services, today announced
that its central laboratory services received Merck & Co., Inc.'s Outstanding
Strategic Collaboration Award.
Covance Central Laboratory Services is one of only 12 suppliers who were
selected from thousands of Merck suppliers. The criteria for receiving this
award included scorecard performance; contributions towards the Key Business
Result (KBR) for Merck; Covance's ability to work with niche suppliers to
further Merck's business; and operational excellence. Covance received the
award at Merck's annual Supplier Recognition Forum.
"Our strategy of operational and service excellence is critical to our
success. We are proud of our Merck team for delivering on this strategy and of
the work that we all have done with Merck as well as the positive impact it
has had on human lives," said Deborah Tanner, President of Covance Central
Laboratory Services and Senior Vice President of Covance Inc. "We are honored
to be recognized for the collaborative spirit, innovation, expertise,
experience, and integrity we bring to our partnerships."
Covance is the most experienced central laboratory services provider in
the world. Since 1986, it has focused solely on clinical trials. In the past
five years alone, it has performed more than 150 million tests; provided
services for more than 3,000 clinical trial protocols; and supported nearly
100,000 investigator sites in 100 countries. It maintains wholly-owned
central laboratories in Indianapolis, Indiana; Geneva, Switzerland; Singapore;
and Shanghai, China.
Covance, with headquarters in Princeton, New Jersey, is one of the
world's largest and most comprehensive drug development services companies
with annual revenues greater than $1.5 billion, global operations in more than
20 countries, and nearly 9,000 employees worldwide. Information on Covance's
products and services, recent press releases, and SEC filings can be obtained
through its website at www.covance.com.
SOURCE Covance

Covance: Media, +1-609-452-2466, Investor, +1-609-452-4807